Source: Myeloma – Hematology Advisor
Researchers sought to determine whether treatment with daratumumab may be associated with trends of improved bone turnover.
Read More
Recent Content
- Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma
- Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
- Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma
- Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
- Circulating miR-448 acts as a potential diagnostic biomarker for multiple myeloma
- Daratumumab-Based Triplet Therapy Shows Benefits for Relapsed/Refractory Multiple Myeloma
- Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia
- Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
- Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model
- A Rare Case of Extra-Medullary Portacaval Plasmacytoma in a Patient With Relapsed Multiple Myeloma